Back
CE / CME
Optimizing Genetic Evaluation in Pediatric Sensorineural Hearing Loss: A Practical Guide for Hearing Specialists
Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit
Physicians: maximum of 0.50 AMA PRA Category 1 Credit™
Nurse Practitioners/Nurses: 0.50 Nursing contact hour
Released: July 30, 2026
Expiration: July 29, 2027
Activity
Genetic Testing in Pediatric SNHL
Genetic testing is being increasingly integrated into the diagnostic evaluation of pediatric SNHL. For otolaryngology healthcare professionals (HCPs), the clinical value of a genetic-backed diagnosis is not limited to identifying etiology. It also informs prognosis, need for syndromic surveillance, family counseling, and treatment planning, including cochlear implant timing and expectations as well as eligibility for emerging and approved genotype-specific therapies.1,2
However, genetic testing results are not always translated into personalized SNHL management strategies consistently. In this module, I will discuss practical patient case examples to help reinforce how otolaryngology HCPs should incorporate genetic testing into patient-centered care planning for pediatric SNHL, while avoiding overinterpretation of uncertain or nonactionable findings.
Patient Case 1: Noah, 10-Month-Old Boy With OTOF-Related Hearing Loss
As an otolaryngologist practicing in an academic medical center and treating pediatric patients, you are with Noah and his family. Noah is a 10-month-old boy who failed his newborn hearing screening bilaterally. Diagnostic auditory brainstem response (ABR) confirmed bilateral severe to profound SNHL. Noah was fit with hearing aids at 3 months old and enrolled in early intervention. His parents report limited responses to sound despite consistent device use.
There is no known family history of childhood hearing loss, and Noah’s parents are unaffected and unrelated.
After evaluation, you determine Noah’s audiologic follow-up shows minimal aided access to speech. In addition, MRI demonstrates normal bilateral cochlear nerves and no cochlear malformation, and CT does not show enlarged vestibular aqueduct. No renal, pigmentary, cardiac, vestibular, or craniofacial findings are documented. Comprehensive gene panel testing for hearing loss identifies biallelic pathogenic variants in the OTOF gene that are consistent with OTOF-related hearing loss, an autosomal recessive nonsyndromic auditory synaptopathy.3
Noah’s parents ask, “Do these results tell us what to expect? Are there any other health problems we should screen for? Should we move forward with cochlear implants? We saw online that gene therapy may be available. Does that apply to Noah?”
Connecting Genetics and Genomics to Clinical Implications
The first step in any case is to determine if the genetic testing results are diagnostic and concordant with the child’s phenotype. In Noah’s case, the positive results for biallelic pathogenic OTOF variants are consistent with OTOF-related hearing loss. OTOF encodes otoferlin, which is important for synaptic transmission from cochlear inner hair cells to the auditory nerve. OTOF-related hearing loss is typically congenital or prelingual and severe to profound, often with preserved cochlear outer hair cell function early in life.3
The American College of Medical Genetics and Genomics (ACMG) clinical practice resource on hearing loss emphasizes that an etiologic diagnosis should be made for all children with confirmed hearing loss. This is critical because the results will inform genetic counseling, support patient education, guide treatment and management, and potentially identify other needs when hearing loss is part of a broader medical condition.4
In Noah’s case, genetic testing helps us move beyond bilateral severe to profound SNHL of unknown etiology to more specific, patient-centered planning. For example, his results provide a likely molecular explanation for hearing loss (ie, biallelic pathogenic OTOF variants), with an inheritance pattern that supports autosomal recessive recurrence counseling in coordination with genetics.
Furthermore, Noah’s phenotype is consistent with cochlear implant consideration because it would bypass the dysfunctional synapse to directly stimulate the functional auditory nerve. This is a critical distinction because hearing aids are unlikely to benefit those with OTOF-related hearing loss. Noah’s genotype also is relevant because novel studies on gene therapy for OTOF-related hearing loss are now clinically relevant.4 Finally, the genetic results alone do not suggest a need for syndromic renal, cardiac, thyroid, retinal, or vestibular surveillance.
Genetic Counseling With Patients’ Families
In pediatric SNHL, a genotype-informed prognosis should be specific but not deterministic. That means the goal for otolaryngology HCPs is to educate patients’ families on what the genetic testing results clarify and what further depends on patient evaluation.
In Noah’s case, the presence of biallelic pathogenic OTOF variants supports a diagnosis of congenital severe to profound genetic hearing loss. This explains why the early use of hearing aids provided limited to no benefit. However, the results do not replace individualized assessment of Noah’s auditory access, developmental trajectory, imaging, family goals, or candidacy for other interventions.1
An example statement to share with Noah’s parents during genetic counseling: “The genetic testing results give us a strong explanation for Noah’s hearing loss. It is consistent with congenital severe to profound genetic hearing loss. Because the hearing aids are not providing adequate access to sound and his auditory nerves are present, we should discuss cochlear implant as an intervention. We would need to complete an evaluation, during which we also can consider gene therapy as long as he meets the eligibility for that.”
Cochlear Implant Evaluation and Setting Expectations
A genetic-backed diagnosis often refines patient evaluation for cochlear implant, but it should not replace HCP assessment of patient candidacy. Otolaryngology HCPs should consider the degree and configuration of patients’ hearing loss, including imaging of the cochlea and cochlear nerve, aided audibility and speech perception when measurable, auditory skill development, duration of hearing loss, any related medical and anesthetic considerations, family communication goals, and available genotype-specific alternatives or adjuncts.5,6
According to genotyped cohort data, genetic diagnoses for pediatric SNHL are associated with differences in severity, progression, and cochlear implant outcomes. This reinforces the value of incorporating genetic testing and genotype results into patient-centered care planning for pediatric SNHL.7,8
For OTOF-related hearing loss, specifically, cochlear implant outcomes generally are favorable because the primary deficit is presynaptic cochlear inner hair cell dysfunction, not an absence or dysfunction of the auditory nerve. That said, HCPs should set expectations appropriately and avoid guaranteeing positive outcomes. Benefits with devices like cochlear implants also depend on patients’ age at implantation, auditory deprivation, anatomy, rehabilitation, developmental factors, and family engagement.9
A balanced statement to share with Noah’s parents during counseling on cochlear implant might look like: “Noah’s diagnosis of genetic hearing loss is generally compatible with meaningful benefit from cochlear implant, especially considering his imaging shows intact cochlear nerves. We still need to complete the standard cochlear implant candidacy process, but genetic testing supports timely referral rather than prolonged management with hearing aids alone when aided auditory access remains limited.”
Feedback on Poll Question 3
Noah’s genotype, phenotype, and imaging support timely cochlear implant evaluation. His genetic testing results also may be relevant to determining eligibility for genotype-specific therapy; therefore, counseling should include both established hearing intervention planning and therapy-specific review. Finally, his genetic diagnosis should inform, not replace, standard evaluation for cochlear implant candidacy.
Surveillance and Interdisciplinary Coordination for Syndromic vs Nonsyndromic Hearing Loss
Not all cases of genetic hearing loss carry the same surveillance implications in follow-up. That is why it is critical that otolaryngology HCPs distinguish between nonsyndromic and syndromic hearing loss because targeted surveillance may be clinically important for certain syndromic cases only. Then there are genes with variable syndromic/nonsyndromic presentations, where patients’ phenotype and genotype must be interpreted carefully. Uncertain findings, such as variants of uncertain significance, should not independently drive major care planning decisions.10
In Noah’s case, his positive results for biallelic pathogenic OTOF variants align most consistently with nonsyndromic auditory synaptopathy. These results do not suggest comprehensive surveillance is needed as would be the case for certain gene mutations associated with retinal, thyroid, or renal disease; cardiac conduction abnormalities; pigmentary findings; or vestibular syndromes. For example, a child with SLC26A4-related SNHL and enlarged vestibular aqueduct may require counseling on Pendred syndrome and thyroid-related surveillance.11 Rather, Noah should be monitored for response to supportive care and potential new manifestations. The focus for OTOF-related hearing loss surveillance generally is routine audiometric follow-up.3
Below is a practical framework for managing pediatric patients with SNHL.10
- Confirm the SNHL type with genetic testing: syndromic vs nonsyndromic and pathogenic or likely pathogenic vs variants of uncertain significance
- Verify inheritance pattern present: monoallelic vs biallelic, autosomal dominant vs recessive, and de novo vs inherited
- Assess concordance with phenotype: audiogram, age of onset, progression, vestibular findings, and imaging.
- Identify surveillance needs: multidisciplinary care with ophthalmology, nephrology, cardiology, endocrinology, vestibular therapy, and/or developmental services, as indicated
- Coordinate further genetic testing and counseling as needed: recurrence risk, parental and cascade testing, and reinterpretation of uncertain findings
For Noah, HCPs should coordinate with genetics for inheritance and recurrence counseling. They do not need to initiate broad syndromic surveillance because his hearing loss is nonsyndromic.
Feedback on Poll Question 4
Biallelic pathogenic variants in the OTOF gene are typically associated with nonsyndromic hearing loss. This supports coordination with genetics for counseling on inheritance, recurrence risk, and family risk. In turn, it does not justify broad surveillance, as is seen in syndromic hearing loss, in the absence of additional clinical features. Surveillance in nonsyndromic hearing loss should be informed by genotype and phenotype rather than reflexive.
Genetic Testing Informs Gene Therapy Evaluation
When pediatric patients are diagnosed with SNHL, their families frequently ask us about gene therapy. This discussion is now clinically relevant for OTOF-related hearing loss, but patient selection must be precise.
There are currently adeno-associated virus vector gene therapies in development, such as AK-OTOF, and in April 2026, the FDA granted accelerated approval to lunsotogene parvec-cwha, a dual adeno-associated virus vector–based gene therapy, for a specific genetic hearing loss. That is, it is indicated to treat pediatric and adult patients with severe to profound or profound SNHL associated with biallelic OTOF variants (molecularly confirmed), preserved outer hair cell function, and no prior cochlear implant.12-14
Although this novel therapy changes standard care planning for children like Noah, it does not mean that every child with genetic SNHL is eligible for this gene therapy. For otolaryngology HCPs, the challenge is to avoid both extremes when counseling patients’ families about gene therapy for OTOF-related hearing loss. Do not overpromise (ie, “Gene therapy can restore hearing for genetic hearing loss”) or dismiss (ie, “Gene therapy is experimental, not relevant”) this novel treatment option.
An example of a balanced statement for Noah’s family may look like: “Noah’s genetic testing results demonstrate hearing loss via the gene for which a gene therapy has recently been approved. That makes this worth discussing with a center experienced in OTOF-related hearing loss and treatment evaluation. At the same time, we should not assume Noah is eligible; an evaluation needs to be completed. We need to consider the full approval criteria for the gene therapy, Noah’s cochlear status, prior treatment, timing, and other standard hearing management options, including cochlear implant.”
A Realistic Management Plan for Noah
A genotype-informed care plan for Noah should include urgent hearing access planning after confirming his diagnosis, including phase, recurrence risk, and family testing implications. Because Noah has limited benefit with hearing aids and bilateral severe to profound SNHL, otolaryngology HCPs should ensure timely referral for cochlear implant evaluation and avoid prolonged auditory deprivation. Furthermore, because his diagnosis of OTOF-related hearing loss is confirmed by genetic testing, otolaryngology HCPs should discuss referral to a center familiar with OTOF-directed gene therapy and surgical considerations with Noah’s family.
Again, it is important to avoid unnecessary surveillance generally associated with syndromic SNHL. Only add surveillance to your follow-up strategy if genotype, phenotype, or evolving clinical findings support it. Then clarify with Noah’s parents that genotype provides important information but does not independently determine clinical decision-making. Note that multidisciplinary care coordination may be necessary. The care team might include pediatric audiology, genetics and genomics, speech-language pathology, surgery, and/or gene therapy experts.
Key Takeaways
Genetic testing should not simply end with an etiologic diagnosis. For otolaryngology HCPs, the real task is to translate genetic testing results into practical care planning for children with SNHL.
For a child like Noah, genetic testing results support a specific diagnosis, inform cochlear implant expectations, limit unnecessary surveillance needs, and urge an emerging discussion on gene therapy. Of note, standard hearing access planning should continue while gene therapy eligibility is clarified.
For pediatric patients with SNHL with other genotypes, case management implications vary. Results might suggest progressive hearing loss; cochlear malformation; vestibular involvement; retinal, thyroid, or renal disease; or cardiac risk. Findings also may be uncertain in nature and should not drive clinical decision-making. That is why the most useful approach is systematic: interpret genetic testing results within the clinical context, coordinate with genetics and genomics experts, and align patients’ care planning with their phenotype, developmental needs, and family goals.